The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
about
The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depressionMolecular cancer prevention: Current status and future directionsChemoprevention of cancer: current evidence and future prospectsJNCI and cancer preventionVitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.Do environmental factors modify the genetic risk of prostate cancer?Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells5α-Reductase inhibitors and risk of high-grade or lethal prostate cancerLong-term survival of participants in the prostate cancer prevention trial.Obesity, body composition, and prostate cancer.A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).Dutasteride for the treatment of prostate-related conditions.Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research.Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT).Dutasteride for the treatment of benign prostatic hyperplasia.Canadian Consensus Conference: The FDA decision on the use of 5ARIs.Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer preventionA population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.A Perspective on Prostate Carcinogenesis and ChemopreventionMetformin use and risk of prostate cancer: results from the REDUCE study.Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsOverdiagnosis of prostate cancer.Obesity and prostate cancer: weighing the evidence.The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.Current status of 5α-reductase inhibitors in prostate disease managementThe association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview SurveyThe Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancerIntroduction: Cancer chemoprevention and its context.Chemoprevention of prostate cancer: an updated view.An introduction to acinar pressures in BPH and prostate cancer.Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Cancer Prevention: Lessons Learned and Future Directions.Prostate Cancer Prevention: Concepts and Clinical Trials.Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5α-reductase inhibitors.Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity.Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
P2860
Q24564068-58AB8580-CC40-45A8-BC9C-4963ED4B87A4Q26797207-D3C95398-33F9-4282-8296-B44834F8DC58Q27000363-D5D1C2EF-8896-45EB-9B23-3ADD7F9C1118Q28389384-4FD23260-9D15-41D1-A17E-5050831DC923Q29620308-352977B1-E867-460A-95B6-9769D3B62DC3Q30528764-E270658A-9989-4BEC-AABB-93D7CCEDB25CQ30621007-2C67E6D7-8C0F-4B87-8E36-B657A23E0279Q33738321-ADC8F5CE-B94E-4CEE-9C49-D03C4E3F0092Q34005866-B1B6BCF3-C363-4CAB-880B-CFDED96CD937Q34077860-28A7962F-D6FB-470A-96CB-7F02904B626BQ34132364-50C90B60-8D95-4809-B0F9-709D5534776CQ34141355-D599976F-193B-4A69-84B5-33BDE74E782DQ34252953-2EC7BA1F-5448-4212-95D0-2514F7A3C047Q34284547-375C218D-9568-4BAA-9784-09A206A6DF6CQ34313221-3C267DB1-CEEB-41F3-8E0D-7D64FFE59948Q34336747-B2E977FF-C64A-4CE5-A5D4-482A3D0FE174Q34349726-C4AF4218-8C1C-4F1C-ADB2-826097F78B18Q35894624-2E2EBA05-3A60-4F78-964A-8E93CE3B7FDDQ36080332-A0E93BE0-BF21-4F12-BD8B-FC4A6BE93E23Q36102847-C2C01859-31E4-4B0A-9313-0D81AA93DE71Q36116269-1FDF2D2E-98AA-4E36-8546-2E02022C5B20Q36296255-0CFD96DB-5570-42E7-848D-AD8B20F12A48Q36413132-781E00BA-D76F-425B-AC45-3B735ED221F2Q36520508-3DB01E5C-7E89-4347-B654-A85CE134FC4CQ36685022-C18E01C2-7016-451A-B191-01F3F2F62A6AQ36728894-C06B49D6-0151-4B78-9D3E-66B55734A4F5Q36778346-DFE59B97-DE9C-48A2-B40C-BD3C39DE5B95Q37205121-01F91E77-7DBA-4484-B81B-668518B1C4F5Q37260055-50D79294-422C-4DF3-B24A-2E5B917A2DBAQ37514273-D3C4F017-94A5-46EC-BF94-6D4F49746DEAQ37975188-5CDC88C8-CCF4-4ED7-8817-102BE7BF3897Q38106624-9641BB36-9E04-46DF-BDD0-E8B21A1F1777Q38256395-0888438D-04A2-41FE-B766-E7F975260D44Q38485721-827D3DF6-2CC6-4995-B8FF-658B1FCE8293Q38571198-003E52E3-7119-4DD2-96C3-9F63D6B4275DQ38652183-C803E48C-CB3A-48C1-8404-F91BFD596AF6Q38766396-1D8B9B57-0E35-4649-B048-AE1A3508FB97Q38942325-618B5FC0-83AC-406E-BD34-E07CE9CBDAC7Q39190804-120CB98B-3233-4FAC-A1D6-EC40A041C8ADQ39844699-8DB692F5-A8FF-4420-AD3B-8D508C337E34
P2860
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
@en
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
@nl
type
label
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
@en
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
@nl
prefLabel
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
@en
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
@nl
P2093
P356
P1476
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
@en
P2093
Jenny J Zhang
Marc R Theoret
Patricia Keegan
Richard Pazdur
Robert Justice
Yang-Min Ning
P356
10.1056/NEJMP1106783
P407
P577
2011-06-15T00:00:00Z